e-learning
resources
Munich 2014
Tuesday, 09.09.2014
ILDs 5
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Successful treatment of alveolar proteinosis by inhaled GM-CSF and intravenous rituximab
S. Fähndrich, P. Lepper, S. Henschke, R. Bals, H. Wilkens (Homburg/Saar, Germany)
Source:
International Congress 2014 – ILDs 5
Session:
ILDs 5
Session type:
Thematic Poster Session
Number:
3771
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Fähndrich, P. Lepper, S. Henschke, R. Bals, H. Wilkens (Homburg/Saar, Germany). Successful treatment of alveolar proteinosis by inhaled GM-CSF and intravenous rituximab. Eur Respir J 2014; 44: Suppl. 58, 3771
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Imaging of complicated pneumonia: what is new?
Related content which might interest you:
Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Clinical features of four children with pulmonary alveolar proteinosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial
Source: International Congress 2014 – ILDs 3
Year: 2014
European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP)
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts
Source: International Congress 2014 – ILDs 2
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Beneficial effect of azithromycin in children with diffuse parenchymal lung disease
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital
Source: International Congress 2014 – ILDs 4
Year: 2014
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome
Source: International Congress 2014 – ILDs 2
Year: 2014
Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
The role of CCR2
+
CD4
+
T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept